Real time display of the vertical beam sizes in LEP using the BEXE X-ray detector and fast VME based computers

Fast X-ray detectors based on CdTe photoconductors have been installed in LEP since the beginning of its operation in 1989. The angular divergence of the high energy photons from the synchrotron radiation (x-rays) and the narrow spacing of the 64 photoconductors of the detector allow a good measurement of vertical beam profiles down to an rms beam size of 300 mm. This paper presents some specific parameters and experimental results of an upgrade program in which the local processing power of the front-end electronics has been increased by a factor 50. Such a powerful tool has allowed a real time display of the time evolution of the vertical beam sizes. An online correlation plot between the electron and positron beam sizes (turn by turn) is also displayed. These online video images are available in the LEP control room and are used in daily operation for luminosity optimisation

Luminosity and Beam Measurements used for Performance Optimisation in the LEP Collider

The vertical beam-beam parameter in LEP reached 0.083 in 1999. In order to achieve and maintain this high performance a number of different observables are continuously monitored and optimised. The beam sizes are measured using X-ray detectors and UV telescopes. The luminosity is determined directly with tungsten-silicon calorimeters and indirectly through an accurate measurement of the beam lifetime. The tune shift is measured from the tune spectrum in collision. Beam-beam deflection scans provide information about the beam sizes and separation at the interaction points. The different measurements are shortly reviewed and their resolution and time response is analysed. Their use for the optimisation of LEP is described

Immune-neuroendocrine and metabolic disorders in human and experimental T. cruzi infection: New clues for understanding Chagas disease pathology

Studies in mice undergoing acute Trypanosoma cruzi infection and patients with Chagas disease, led to identify several immune-neuroendocrine disturbances and metabolic disorders. Here, we review relevant findings concerning such abnormalities and discuss their possible influence on disease physiopathology.Fil: González, Florencia Belén. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; ArgentinaFil: Villar, Silvina Raquel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; ArgentinaFil: Pacini, María Florencia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; ArgentinaFil: Bottasso, Oscar Adelmo. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; ArgentinaFil: Perez, Ana Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario. Instituto de Inmunología Clinica y Experimental de Rosario. Universidad Nacional de Rosario. Facultad de Ciencias Médicas. Instituto de Inmunología Clinica y Experimental de Rosario; Argentin

Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In Vivo

Chagas disease caused by Trypanosoma cruzi is an important cause of mortality and morbidity in Latin America but no vaccines or safe chemotherapeutic agents are available. Combined therapy is envisioned as an ideal approach since it may enhance efficacy by acting upon different cellular targets, may reduce toxicity and minimize the risk of drug resistance. Therefore, we investigated the activity of benznidazole (Bz) in combination with the diamidine prodrug DB289 and in combination with the arylimidamide DB766 upon T. cruzi infection in vivo. The oral treatment of T.cruzi-infected mice with DB289 and Benznidazole (Bz) alone reduced the number of circulating parasites compared with untreated mice by about 70% and 90%, respectively. However, the combination of these two compounds decreased the parasitemia by 99% and protected against animal mortality by 100%, but without providing a parasitological cure. When Bz (p.o) was combined with DB766 (via ip route), at least a 99.5% decrease in parasitemia levels was observed. DB766+Bz also provided 100% protection against mice mortality while Bz alone provided about 87% protection. This combined therapy also reduced the tissular lesions induced by T. cruzi infection: Bz alone reduced GPT and CK plasma levels by about 12% and 78% compared to untreated mice group, the combination of Bz with DB766 resulted in a reduction of GPT and CK plasma levels of 56% and 91%. Cure assessment through hemocultive and PCR approaches showed that Bz did not provide a parasitological cure, however, DB766 alone or associated with Bz cured ≥13% of surviving animals

Small t Physics at the TEVATRON Collider

The first physics run of the superconducting Tevatron Collider at Fermilab ended this morning. A status report will be presented on the progress of the small angle elastic scattering and total cross section experiment, E710. The goals of this experiment are to measure the total proton-antiproton cross section from ..sqrt..s = 300 to 2000 GeV, the slope of the diffraction peak and rho, the ratio of the real to imaginary part of the forward scattering amplitude, at these energies. 1 ref., 8 figs